|
(Health-NewsWire.Net, October 08, 2021 ) The Report "Risk-based Monitoring Software Market by End User (Pharma & Biopharmaceutical Co., Medical Device Co., CROs), Delivery Mode (Web Hosted, On-premise, Cloud-based), Type (Enterprise, Site), Component (Software, Services) - Global Forecast to 2025", published by MarketsandMarkets™, the RBM software market is expected to reach USD 511 million by 2025 from USD 273 million in 2020, at a CAGR of 13.3%.
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=102112429
The key factors driving the growth of this market are the cost and time efficiency of RBM solutions, rising number of clinical trials, and increasing government funding and grants to support clinical trials
By type, the Enterprise RBM Software segment is expected to account for the largest share of the Risk-based Monitoring Software Market in 2020
Based on type, the market is segmented into Enterprise RBM Software and Site RBM Software. In 2020, the Enterprise RBM Software segment is expected to command the largest share of the market. The large share of this segment can be attributed to the widespread adoption of enterprise RBM software by end-users as it allows all authorized professionals to have access to clinical trial data and metrics placed at a centralized location.
By component, the software segment is expected to account for the largest share of the RBM software market in 2020
Based on the component, the market is segmented into Software and Services. In 2020, the software segment is expected to command the largest share of the market. The large share of this segment can be attributed to the increasing R&D expenditure in the life science and clinical research industries, increasing number of clinical trials, and rising customer base
Browse in-depth TOC on "Risk-based Monitoring Software Market"
114 – Tables
30 – Figures
137 – Pages
By delivery mode, the delivery mode segment is expected to account for the largest share of the Risk-based Monitoring Software Market in 2020
Based on delivery mode, the market is segmented into Web-based (On-demand), Licensed Enterprise (On-premise), and Cloud-based (SaaS). In 2020, the Web-based (On-demand) segment is expected to command the largest share of the market. The large share of this segment can be attributed to the advantages offered by web-based software, such as easy access, improved productivity, time efficiency, and cost-efficiency.
By end-user, the pharmaceutical and biopharmaceutical companies end-user segment is expected to account for the largest share of the Risk-based Monitoring Software Market in 2020
Based on end user, the market is segmented into pharmaceutical and biopharmaceutical companies, CROs, medical device companies, and other end users. In 2020, the pharmaceutical and biopharmaceutical companies segment is expected to command the largest share of the RBM software market. The increasing R&D expenditure of pharmaceutical and biopharmaceutical companies is the major factor driving the growth of this end-user segment.
Request Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=102112429
North America to dominate the Risk-based Monitoring Software Market in 2020
North America, Europe, Asia Pacific, and the Rest of the World (RoW) are the regions considered for geographic analysis of the global market study. North America is expected to account for the largest share of the global market. The large share of North America is attributed to the to the increased adoption of RBM software solutions for clinical trials.
The prominent players in the global Risk-based Monitoring Software Market include Oracle (US), Medidata Solutions (US), and Parexel (US). Other prominent players in the market are Bioclinica (US), Bio-Optronics (US), IBM Corporation (US), DATATRAK (US), Veeva Systems (US), DSG (US), MasterControl (US), ERT (US), Forte Research Systems (US), MedNet Solutions (US), ArisGlobal (US), Anju Software (US), MaxisIT (US), Techsol Corporation (US), OpenClinica (US), CRF Health (US), and Covance (US).
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
MarketsandMarkets™
Mr. Aashish Mehra
1-888-600-6441
raviraj.tak@marketsandmarkets.com
Source: EmailWire.Com 
|
